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Background: Lipopolysaccharide/D-galactosamine (LPS/GalN)einduced hepatic injury is an
experimental model of fulminant hepatic failure in which tumor necrosis factor alpha
(TNF-a) plays a pivotal role. Moreover, it was reported from our laboratory that interleukin
(IL) 17A enhanced production of TNF-a by the Kupffer cell.
Objective: The purpose of this study was to determine the role of IL-17A in LPS/GalN-
induced hepatic injury in mice.
Methods: LPS/GalN was injected into three mouse models: wild-type (WT) mice, IL-17A
knockout (KO) mice, or IL-17A KO mice treated with recombinant mouse (rm) IL-17A
homodimer (KO þ rmIL-17A). Survival was assessed for 24 h after LPS/GalN injection,
and histopathologic findings were evaluated at various time points after LPS/GalN injection
for neutrophil and apoptosis markers. After LPS/GalN injection, expression of the inflam-
matory mediators TNF-a, IL-6, monocyte chemotactic protein 1, IL-17A, high-mobility
group box 1, and soluble intercellular adhesion molecule 1 was assessed in serum by
enzyme-linked immunosorbent assay.
Results: Survival was higher in KO mice compared with WT mice after LPS/GalN injection.
However, in KO þ rmIL-17A mice, mortality was not significantly different compared to the
other groups. Neutrophil infiltration and apoptosis were significantly greater in WT mice
than KO mice. Furthermore, serum alanine aminotransferase, serum TNF-a, monocyte
chemotactic protein 1, IL-17A, high-mobility group box 1, and soluble intercellular adhe-
sion molecule 1 levels were also significantly greater in WT mice than KO mice. In
KO þ rmIL-17A mice, these levels were similar to those in WT mice.
Conclusions: IL-17A is a key regulator in hepatic injury caused by neutrophil-induced in-
flammatory responses after LPS/GalN injection.
ª 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction multiple organ failures [1,2]. Fulminant hepatic injury has aFulminant hepatic injury is often a fatal condition resulting in
hepatocellular apoptosis and hemorrhagic necrosis, leading toSurgery, Faculty of Medic
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direct cytotoxicity, and macrophage-mediated hepatic injury,
occurs in lipopolysaccharide (LPS)-treated mice [7]. Further-
more, D-galactosamine (GalN; as a specific hepatotoxic agent)
has been shown to increase sensitivity to the lethal effects of
endotoxin [8]. Hepatic injury induced by LPS in combination
with GalN is similar to acute hepatic failure in the clinical
setting [9]. Therefore, LPS/GalN-induced hepatic injury is used
as an animal model of fulminant hepatic injury in humans
[10e12].
The hepatic macrophage, the Kupffer cell, is known to
produce a variety of growth and immunomodulating media-
tors that have stimulatory and inhibitory effects on hepatic
injury [13]. It has been reported that hepatic macrophages are
the major source of tumor necrosis factor alpha (TNF-a) and
interleukin (IL) 6, and depletion of hepatic macrophages im-
pairs hepatic injury [14e16]. IL-17A was originally described
and cloned by Rouvier et al. [17] and named cytotoxic T-
lymphocyte-associated serine esterase 8. IL-17A, a cytokine
produced by various cells including Th17, T cells, and CD8-
positive T cells, is elevated in inflammatory conditions, such
as inflammatory myopathies, rheumatoid arthritis, asthma,
ulcerative colitis, and multiple sclerosis [18e22]. It was re-
ported from our laboratory that IL-17A increases TNF-a pro-
duction by isolated Kupffer cells in vitro [23]. These results
support the hypothesis that IL-17A may be involved in
fulminant hepatic failure; however, its role has not been fully
elucidated. Therefore, the specific purpose of the present
study is to investigate the role of IL-17A in fulminant hepatic
failure.2. Materials and methods
2.1. Animals
Malewild-type (WT)mice (C57BL/6, 20e25 g, 8e9 weeks of age,
obtained from Jackson Laboratories, Bar Harbor, ME) andmale
IL-17A knockout (KO) mice (backcrossed onto C57BL/6) were
housed in a clean, temperature-controlled environment with
a 12-h light-dark cycle and were given free access to regular
laboratory chow diet and water for several days. All animals
received humane care, and the study protocols were approved
by the Committee of Laboratory Animals at University of
Yamanashi according to institutional guidelines. Mortality
study was performed with eight animals of each groups, and
time point study was performed with six to eight animals at
each time points (0, 1, 2, 4, and 8 h after LPS/GalN injection).
2.2. Treatment with recombinant mouse IL-17A
homodimer or phosphate-buffered saline in IL-17A KO mice
before LPS/GalN injection
Recombinant mouse (rm) IL-17A homodimer (R&D Systems,
Minneapolis, MN) was diluted in sterile phosphate-buffered
saline (PBS) and administered intraperitoneally (i.p.) at a
dose of 0.5 mg per mouse in a total volume of 100 mL at 6 h
before LPS/GalN i.p. (n ¼ 8). The concentration of rmIL-17A
homodimer to be administered was determined in pre-
liminary dose-response experiments, which showed that0.5-mg IL-17A consistently produced a significant influx of
neutrophils [23].
2.3. Treatment of mice with LPS/GalN injection
LPS andD-GalNwere purchased from SigmaAldrich (St. Louis,
MO). The mice were divided into the following groups: WT
mice treated with LPS/GalN and PBS (WT mice group), IL-17A
KO mice treated with LPS/GalN and PBS (KO mice group) and
IL-17A KO mice treated with LPS/GalN and rmIL-17A (KO
[rmIL-17A] mice group). LPS/GalN was dissolved in 200-mL
saline and injected i.p. at 2.5-mg/kg LPS and 300-mg/kg GalN.
2.4. Collection of samples
Blood samples were collected via the inferior vena cava at 0, 1,
2, 4, and 8 h after LPS/GalN injection, centrifuged, and stored
at 80C until assay. Tissue samples were also collected and
weighed at designated times after i.p. and were stored at
80C for further analysis. Samples were fixed in formalin or
acetone, embedded in paraffin, and serially sectioned.
2.5. Immunohistochemical staining for neutrophils or
Tdt-mediated dUTP-biotin nick labeling assay
For immunohistochemical staining of IL-17A in the liver,
formalin-fixed, paraffin-embedded tissue specimens were cut
into 4-mm sections. Each section was mounted on a silane-
coated glass slide, deparaffinized, and soaked for 15 min at
room temperature in 0.3% H2O2/methanol to block endoge-
nous peroxidase. The rat antimouse neutrophil Ab (1/500,
Caltag Laboratories, South San Francisco, CA) was applied
overnight at 4C. Peroxidase-linked secondary antibodies and
diaminobenzidine (VECTASTAIN Elite ABC Kit; Vector Labo-
ratories, Burlingame, CA) were used to detect specific binding.
Sections were counterstained with hematoxylin. Morpho-
metric analysis of immunoreactive neutrophils in liver sec-
tions was performed by quantifying the total numbers of
immunoreactive cells in five random at 400  magnification
fields (four independent animals were analyzed for each
experimental group).
Apoptosis was evaluated by the Tdt-mediated dUTP-biotin
nick labeling (TUNEL) method using ApopTag Plus Peroxidase
in Situ Apoptosis Detection Kit (Millipore, Billerica, MA) ac-
cording to the manufacturer’s instructions. Methyl green
(0.5% wt:vol) was used for counterstaining. TUNEL-positive
cells were observed under microscopy. At least five fields
were examined for calculation of apoptosis index.
2.6. Measurement of plasma alanine aminotransferase
Plasma alanine aminotransferase (ALT) levels were measured
to assess hepatic parenchymal damage using FUJI DRI-CHEM
analyzers (Fujifilm Co, Tokyo, Japan).
2.7. Measurement of serum cytokines
Determination of serum TNF-a (R&D Systems, Minneapolis,
MN), IL -6 (R&D Systems, Minneapolis, MN), sICAM-1(CD54)
(R&D Systems, Minneapolis, MN), CCL2/JE/MCP-1 (R&D
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Diego, CA) levels was performed using enzyme-linked
immunosorbent assay kits, and serum high-mobility group
box 1 (HMGB1) levels were measured using the HMGB1 ELISA
kit 2 (Central Institute, Shino-Test, Kanagawa, Japan).
2.8. Statistical analysis
Data were expressed as mean  standard error of the mean.
Survival at 24 h was compared by KaplaneMeier analysis and
log rank statistics. Statistical differences between mean
values were analyzed by analysis of variance with Bonferro-
ni’s post hoc test. A P value less than 0.05 was considered
significant.Fig. 1 e Effects of LPS/GalN injection on mortality and
serum ALT levels after LPS/GalN injection. (A) Mortality
was determined as described in Materials and methods
(n [ 8 in each group). *P< 0.03 compared with KO by the
log rank test. (B) Liver body weight ratio after LPS/GalN
injection. Liver tissue was collected and weighed at the
designated times after LPS/GalN injection. White box, WT
mice; black box, KO mice; and gray box, KO D rmIL-17A.
Data represent the mean ± standard error of the mean
(n[ 6e8 in each group). *, P< 0.01 by analysis of variance
with Bonferroni’s post hoc test. (C) Serum ALT levels after
LPS/GalN injection. Blood was collected via the inferior
vena cava at the designated times after LPS/GalN injection,
and serum ALT levels were determined as described in
Materials and methods. Data represent the
mean ± standard error of the mean (n [ 8 in each group).
*, P< 0.001 compared with WT; and **, P< 0.01 compared
with KO D rmIL-17A by analysis of variance with
Bonferroni’s post hoc test.3. Results
3.1. Effects of LPS/GalN injection on mortality
In the WT mice, mortality was 50% at 24 h after LPS/GalN in-
jection. In contrast, all KOmice survived at 24 h after injection.
There were significant differences in the mortality between
the WT mice and the KO mice. Furthermore, in the KO mice
treated with rmIL-17A, mortality was 25% at 24 h after LPS/
GalN injection. Thus, mortality was higher than in the KO
mice treated with rmIL-17A than the untreated KO mice
(Fig. 1A).
3.2. Liver-to-body weight ratio and serum ALT levels
In the WT mice, liver-to-body weight ratio increased from
4.8%e6.1% at 24 h after LPS/GalN injection. On the other hand,
in the KOmice, liver-to-bodyweight ratio did not change until
4 h after LPS/GalN injection; at the 8-h time point, liver-to-
body weight ratio slightly increased from 4.5%e5.0%. There
were significant differences in the ratios of liver-to-body
weight between the WT mice and the KO mice. Furthermore,
in the KO mice treated with rmIL-17A, liver-to-body weight
ratio gradually increased from 4.6%e5.8% at 24 h time point
after LPS/GalN injection. The ratios of liver-to-body weight
were not significantly different between the WTmice and the
KO mice treated with rmIL-17A (Fig. 1B).
In the WT mice, serum ALT levels increased to about 6000
IU/L at 8 h after LPS/GalN injection. In the KO mice, however,
the levels were blunted to 25% of levels observed in the WT
mice. There were significant differences in the serum ALT
levels between the WT mice and the KO mice. In the KO mice
treated with rmIL-17A, the serum ALT levels were slightly
lower than those in the WT mice. There were significant dif-
ferences between the KO mice treated with rmIL-17A and the
KO mice (Fig. 1C).
3.3. LPS/GalN-induced hepatic injury
Severe hemorrhage, vascular congestion, and hepatic necrosis
were observed in the WT mice after LPS/GalN injection
(Fig. S1A and D). In contrast, in the KO mice, these pathologic
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more, in the KO mice treated with rmIL-17A, pathologic
changes were similar to those in the WTmice (Fig. S1C and F).3.4. Evaluation of population and distribution of
neutrophils in the liver
To evaluate the population and distribution of neutrophils in
the liver, immunohistochemical staining for neutrophils was
performed. In the animals without LPS/GalN injection, the
number of neutrophils was minimal (Figs. S2 and S4). But,
after LPS/GalN injection, accumulation of neutrophils
increased significantly in the WT mice. Accumulation of
neutrophils was blunted in the KO mice. Moreover, in the KO
mice treated with rmIL-17A, the number of infiltrating neu-
trophils was similar to that in the WT mice.3.5. Evaluation of hepatocyte apoptosis
In all groups studied, the number of TUNEL-positive cells was
undetected just after LPS/GalN injection. The number of
TUNEL-positive cells increased at 8 h after LPS/GalN injection
in the WT mice (Figs. S3 and S4). However, the number was
minimal in the KOmice at the same time point. In the KOmice
treated with rmIL-17A, the number of TUNEL-positive cells
was similar to that in the WT mice at 8 h after LPS/GalN
injection.Fig. 2 e Serum TNF-a and IL-6 levels after LPS/GalN
injection. Serum TNF-a and IL-6 levels were evaluated as
described in the Materials and methods (n [ 8 in each
group). Data represent mean ± standard error. (A) serum
TNF-a levels; and (B) serum IL-6 levels. *, P< 0.05
compared withWT; **, P< 0.05 compared with KOD rmIL-
17A by analysis of variance with Bonferroni’s post hoc test.3.6. Serum proinflammatory cytokine levels after
LPS/GalN injection
Serum TNF-a levels peaked at 1 h after LPS/GalN injection in
the WT mice (Fig. 2A). Although in the KO mice the peak was
also observed at 1 h after LPS/GalN injection, the levels were
significantly lower comparedwith those in theWT at 1 and 2 h
after LPS/GalN injection. The serum TNF-a concentrations
were 1.6-fold greater in the WT mice than in the KO mice at 1
and 2 h after LPS/GalN injection. Furthermore, serum TNF-a
levels were significantly higher in the KO mice treated
with rmIL-17A comparedwith those in the KOmice at 1 h after
LPS/GalN injection.
Serum IL-6 levels peaked at 1 and 2 h after LPS/GalN
injection in the WT mice (Fig. 2B). There were no significant
differences in serum IL-6 levels in each group. In the WT
mice, serum IL-17A levels increased gradually from 4 h after
LPS/GalN injection.
Serum IL-17A levels were not detected, as expected, in the
KO mice (Fig. 3A). In the KO mice treated with rmIL-17A,
however, values declined from 80e30 pg/mL at 2 h after LPS/
GalN injection and then plateaued.
Serum monocyte chemotactic protein (MCP) 1 levels
peaked at 2 h after LPS/GalN injection in theWTmice (Fig. 4A).
Although serum MCP-1 levels also increased in the KO mice,
they were significantly lower compared with those in the WT
mice at 1, 4, and 8 h after LPS/GalN injection. In the KO mice
treated with rmIL-17A, the serum MCP-1 levels peaked at 4 h
after LPS/GalN injection. The levels were significantly higher
compared with those in the KO mice at 1, 4, and 8 h after LPS/
GalN injection.3.6.1. Serum HMGB-1 levels after LPS/GalN injection
Serum HMGB-1 levels increased at 8 h in the WT mice after
LPS/GalN injection (Fig. 3B). In contrast, serum HMGB-1 levels
were significantly lower in both the KO mice (29 ng/mL) and
the KOmice treated with rmIL-17A (75 ng/mL) compared with
those in the WT mice (151 ng/mL) at 8 h after LPS/GalN
injection.3.7. Inflammation-related adhesion molecule expression
after LPS/GalN injection
Serum soluble intercellular adhesion molecule (sICAM) 1
levels increased gradually in the WT mice after LPS/GalN in-
jection (Fig. 4B). On the contrary, serum sICAM1 levels were
significantly lower in the KOmice compared with those in the
WTmice at 8 h after LPS/GalN injection. In the KOmice treated
with rmIL-17A, the serum sICAM1 levels increased gradually.
Serum sICAM1 levels were significantly higher in the KOmice
treated with rmIL-17A compared with those of the KOmice at
8 h after LPS/GalN injection.
Fig. 3 e Serum IL-17A and HMGB-1 levels after LPS/GalN
injection. Serum IL-17A and HMGB-1 levels were evaluated
as described in the Materials and methods (n [ 8 in each
group). Data represent mean ± standard error. (A) serum IL-
17A levels; and. (B) serum HMGB-1 levels. *, P< 0.01
compared with WT; **, P< 0.05 compared with WT; and
#, P< 0.05 compared with KO D rmIL-17A by analysis of
variance with Bonferroni’s post hoc test.
Fig. 4 e Serum MCP-1 and sICAM-1 levels after LPS/GalN
injection. SerumMCP-1 and sICAM-1 levels were evaluated
as described in the Materials and methods (n [ 8 in each
group). Data represent mean ± standard error. (A) serum
MCP-1 levels; and (B) serum sICAM-1 levels. *, P< 0.05
compared withWT; **, P< 0.05 compared with KOD rmIL-
17A; #, P< 0.01 compared with KO D rmIL-17A; and
##, P< 0.01 compared with WT and KO D rmIL-17A by
analysis of variance with Bonferroni’s post hoc test.
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4.1. The role of IL-17A in fulminant hepatic injury
In the present study, liver-to-body weight ratio and ALT levels
decreased significantly in the KOmice compared with theWT
mice after LPS/GalN injection (Fig. 1B and C). In the KO mice
treated with rmIL-17A, liver-to-body weight ratio and ALT
levels increased compared with the KO mice after LPS/GalN
injection. Furthermore, hepatic injury was also prevented in
the KO mice compared with the WT mice (Fig. S1). These are
suggesting that IL-17A is involved in the hepatic injury
induced by LPS/GalN injection.
Inflammatory cytokines, especially TNF-a, have been
linked to the pathogenesis of hepatocyte apoptosis and
hepatic injury [15]. In the present study, serum TNF-a levels
increased and peaked at 1 h after LPS/GalN injection in theWT
mice. On the other hand, in the KO mice, serum TNF-a levels
were significantly lower compared with those in the WTmice(Fig. 2A). Furthermore, in the KO mice treated with rmIL-17A,
serum TNF-a levels were significantly higher than in the KO
mice (Fig. 2A). Thus, IL-17A played a pivotal role in TNF-a
production in this model.
IL-6 also plays a key role in fulminant hepatic failure
[24,25]. In the present study, serum IL-6 expression was not
significantly different between the WTmice and the KOmice.
Both Th17 and regulatory T (T-reg) cells can develop from
naı¨ve CD4þ T cell precursors in the presence of transforming
growth factor (TGF) alpha [26]. In addition to TGF-a, differen-
tiation from these cells to Th17 also requires IL-6 [27]. It was
reported that once the T-reg cell differentiation pathway gains
ascendancy, T-reg cells inhibit the generation of Th17 cells at
mucosal surfaces [27,28]. Based on these reports, the same
expression of IL-6 between the KO mice and WT mice may be
due to negative feedback of lack from the IL-17A in the KO
mice [29].
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liver and the expression of inflammatory cytokines
Impairment of neutrophil migration is critical to the bacte-
rial clearance from infection foci [29]. It has been reported
that IL-17A plays a pivotal role in regulating the recruitment
of neutrophils and granulopoiesis [30,31]. sICAM-1 is
involved in binding lymphocytes to antigen-presenting cells
and endothelial cells, leading to lymphocyte activation.
Expression of sICAM-1 increase because of a variety causes,
such as hepatitis, virus infection, toxic insult, alcoholism,
autoimmunity, drugs, ischemia/reperfusion, and schistoso-
miasis japonica [4,9,11,22,32,33]. It has also been reported
that IL-17A induces CXC chemokine-mediated neutrophil
migration and promotes neutrophil-endothelial cell adher-
ence through induction of sICAM-1 expression [34,35]. In the
present study, sICAM-1 expression in the KO mice was
blunted by about 30% compared with that in the WT mice
(Fig. 4B). Alternatively, MCP-1, a known proinflammatory
cytokine, promotes inflammation in tissue infiltration of
lymphocytes and recruits NK and NKT cells to inflammation.
IL-17A also suppresses MCP-1 expression [35]. In the present
study, the expression of MCP-1 was also blunted in the KO
mice compared with the WT mice (Fig. 4A). As a result, the
number of neutrophils in the liver was significantly blunted
in the KO mice (Figs. S1 and S4A). Thus, IL-17 is involved in
infiltrating neutrophils into the liver, thus inducing che-
moattractant factors, such as sICAM1 and MCP-1 in this
model.
The LPS/GalN-induced hepatic injury causes massive
increases in serum inflammatory cytokines [24,36]. In the
present study, serum TNF-a levels increased after LPS/GalN
injection in the WT mice. Increases in TNF-a levels lead to
the induction of HMGB1. It has been reported that the
HMGB1-TLR4-IL-23-IL-17A pathway induces the generation
of IL-17-producing T cells, which mediates hepatocyte
apoptosis [37]. Indeed, expression of both IL-17A and
HMGB1 increased significantly in the WT mice (Fig. 3),
expression of HMGB1 was blunted significantly by 80% in
the KO mice at 8 h after LPS/GalN injection (Fig. 3A).
Furthermore, hepatocyte apoptosis increased in the WT
mice. In contrast, in the KO mice, expression of both IL-17A
and HMGB1 and hepatocyte apoptosis decreased signifi-
cantly compared with the WT mice (Figs. 3 and S4B). Thus,
expression of HMGB1 induced by IL-17A may play an
important role in apoptosis in LPS/GalN-induced hepatic
injury. Taken together, these results indicate that IL-17A
plays a pivotal role in fulminant hepatic injury by
inducing inflammatory cytokines, leading to infiltrating
neutrophils in inflammatory foci. Therefore, it is possible
that IL-17A may be a new therapeutic target as well as
HMGB-1 in fulminant hepatitis [38,39].
Fulminant hepatitis was mild in the IL-17A KO mice
compared with the WT mice and the KO mice treated with
rmIL-17A. Therefore, although lack of IL-17A reduces the
hepatitis induced by LPS/GalN, we think that there are most
likely additional pathways involved in the development of
hepatitis following LPS/GalN administration.5. Conclusions
The lack of IL-17A decreases the serum cytokine and chemo-
kine levels, and all animals survived after LPS/GalN treatment.
These results suggest that IL-17A plays one of the important
roles in fulminant hepatic injury.
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